AbbVie Inc. $ABBV Position Decreased by BBR Partners LLC

BBR Partners LLC reduced its holdings in AbbVie Inc. (NYSE:ABBV) by 7.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 54,244 shares of the company’s stock after selling 4,280 shares during the quarter. AbbVie accounts for 0.6% of BBR Partners LLC’s holdings, making the stock its 17th biggest position. BBR Partners LLC’s holdings in AbbVie were worth $10,069,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. FF Advisors LLC lifted its position in shares of AbbVie by 3.6% during the 2nd quarter. FF Advisors LLC now owns 1,539 shares of the company’s stock valued at $286,000 after acquiring an additional 53 shares during the last quarter. Landaas & Co. WI ADV raised its position in shares of AbbVie by 1.1% during the second quarter. Landaas & Co. WI ADV now owns 4,955 shares of the company’s stock worth $920,000 after purchasing an additional 53 shares during the period. Bernardo Wealth Planning LLC lifted its holdings in shares of AbbVie by 2.9% during the second quarter. Bernardo Wealth Planning LLC now owns 1,909 shares of the company’s stock valued at $354,000 after purchasing an additional 53 shares during the last quarter. LifeSteps Financial Inc. boosted its position in shares of AbbVie by 0.7% in the 2nd quarter. LifeSteps Financial Inc. now owns 7,358 shares of the company’s stock valued at $1,366,000 after purchasing an additional 54 shares during the period. Finally, Silicon Valley Capital Partners raised its holdings in AbbVie by 10.8% during the 1st quarter. Silicon Valley Capital Partners now owns 573 shares of the company’s stock worth $118,000 after buying an additional 56 shares during the period. Institutional investors and hedge funds own 70.23% of the company’s stock.

AbbVie Trading Down 0.2%

AbbVie stock opened at $223.45 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The stock has a market cap of $394.92 billion, a P/E ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36. The company’s fifty day simple moving average is $227.25 and its 200-day simple moving average is $209.59.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm had revenue of $15.78 billion during the quarter, compared to analysts’ expectations of $15.58 billion. During the same quarter last year, the firm earned $3.00 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio is currently 496.97%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ABBV. Cantor Fitzgerald set a $250.00 target price on shares of AbbVie and gave the stock an “overweight” rating in a report on Thursday, October 9th. Scotiabank started coverage on shares of AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price objective for the company. Citigroup cut their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, October 8th. Finally, Erste Group Bank lowered AbbVie from a “buy” rating to a “hold” rating in a research report on Tuesday, October 14th. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $244.55.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.